Activation of the nuclear factor erythroid 2-related factor-2 (Nrf2)/heme oxygenase-1 (HO-1) pathway inhibits the progression of inflammation and reduces ROS production and thus has been a potential therapeutic target for AD (39–42). The gene discussed is NFE2L2; the disease is Alzheimer disease.